SELECT data_key, data_value
FROM xf_data_registry
WHERE data_key IN ('options', 'languages', 'contentTypes', 'codeEventListeners', 'deferredRun', 'simpleCache', 'addOns', 'defaultStyleProperties', 'routeFiltersIn', 'routeFiltersOut', 'routesPublic', 'nodeTypes', 'bannedIps', 'discouragedIps', 'styles', 'displayStyles', 'userBanners', 'smilies', 'bbCode', 'threadPrefixes', 'userTitleLadder', 'reportCounts', 'moderationCounts', 'userModerationCounts', 'notices', 'userFieldsInfo')
Run Time: 0.001615
Select Type | Table | Type | Possible Keys | Key | Key Len | Ref | Rows | Extra |
---|
SIMPLE | xf_data_registry | range | PRIMARY | PRIMARY | 27 | | 26 | Using where |
SELECT data_key, data_value
FROM xf_data_registry
WHERE data_key IN ('brListenerClasses', 'brBriviumAddOns')
Run Time: 0.000157
Select Type | Table | Type | Possible Keys | Key | Key Len | Ref | Rows | Extra |
---|
SIMPLE | xf_data_registry | range | PRIMARY | PRIMARY | 27 | | 2 | Using where |
SELECT *
FROM xf_brivium_addon
ORDER BY addon_id
Run Time: 0.000212
Select Type | Table | Type | Possible Keys | Key | Key Len | Ref | Rows | Extra |
---|
SIMPLE | xf_brivium_addon | index | | PRIMARY | 77 | | 1 | |
INSERT INTO xf_data_registry
(data_key, data_value)
VALUES
(?, ?)
ON DUPLICATE KEY UPDATE
data_value = VALUES(data_value)
Params: brBriviumAddOns, a:0:{}
Run Time: 0.000127
SELECT session_data
FROM xf_session
WHERE session_id = ?
AND expiry_date >= ?
Params: 05196f286475a452e9dec295596596f0, 1716186678
Run Time: 0.000490
Select Type | Table | Type | Possible Keys | Key | Key Len | Ref | Rows | Extra |
---|
SIMPLE | xf_session | const | PRIMARY,expiry_date | PRIMARY | 34 | const | 1 | |
SELECT cache_value
FROM xf_permission_combination
WHERE permission_combination_id = ?
Params: 1
Run Time: 0.000345
Select Type | Table | Type | Possible Keys | Key | Key Len | Ref | Rows | Extra |
---|
SIMPLE | xf_permission_combination | const | PRIMARY | PRIMARY | 4 | const | 1 | |
SELECT thread.*
,
user.gender, user.avatar_date, user.gravatar,
NULL AS thread_read_date,
0 AS thread_reply_banned,
0 AS thread_is_watched,
'' AS draft_message, NULL AS draft_extra
FROM xf_thread AS thread
LEFT JOIN xf_user AS user ON
(user.user_id = thread.user_id)
WHERE thread.thread_id = ?
Params: 370235
Run Time: 0.000786
Select Type | Table | Type | Possible Keys | Key | Key Len | Ref | Rows | Extra |
---|
SIMPLE | thread | const | PRIMARY | PRIMARY | 4 | const | 1 | |
SIMPLE | user | const | PRIMARY | PRIMARY | 4 | const | 1 | |
SELECT node.*, forum.*
,
permission.cache_value AS node_permission_cache,
NULL AS forum_read_date
FROM xf_forum AS forum
INNER JOIN xf_node AS node ON (node.node_id = forum.node_id)
LEFT JOIN xf_permission_cache_content AS permission
ON (permission.permission_combination_id = 1
AND permission.content_type = 'node'
AND permission.content_id = forum.node_id)
WHERE node.node_id = ?
Params: 25
Run Time: 0.000630
Select Type | Table | Type | Possible Keys | Key | Key Len | Ref | Rows | Extra |
---|
SIMPLE | forum | const | PRIMARY | PRIMARY | 4 | const | 1 | |
SIMPLE | node | const | PRIMARY | PRIMARY | 4 | const | 1 | |
SIMPLE | permission | const | PRIMARY | PRIMARY | 35 | const,const,const | 1 | |
SELECT post.*
,
thread.*, thread.user_id AS thread_user_id, thread.username AS thread_username,
thread.post_date AS thread_post_date,
post.user_id, post.username, post.post_date,
bb_code_parse_cache.parse_tree AS message_parsed, bb_code_parse_cache.cache_version AS message_cache_version,
user.*, IF(user.username IS NULL, post.username, user.username) AS username,
user_profile.*,
user_privacy.*,
signature_parse_cache.parse_tree AS signature_parsed, bb_code_parse_cache.cache_version AS signature_cache_version,
session_activity.view_date AS last_view_date,
0 AS like_date
FROM xf_post AS post
INNER JOIN xf_thread AS thread ON
(thread.thread_id = post.thread_id)
LEFT JOIN xf_bb_code_parse_cache AS bb_code_parse_cache ON
(bb_code_parse_cache.content_type = 'post' AND bb_code_parse_cache.content_id = post.post_id)
LEFT JOIN xf_user AS user ON
(user.user_id = post.user_id)
LEFT JOIN xf_user_profile AS user_profile ON
(user_profile.user_id = post.user_id)
LEFT JOIN xf_user_privacy AS user_privacy ON
(user_privacy.user_id = post.user_id)
LEFT JOIN xf_bb_code_parse_cache AS signature_parse_cache ON
(signature_parse_cache.content_type = 'signature' AND signature_parse_cache.content_id = post.user_id)
LEFT JOIN xf_session_activity AS session_activity ON
(post.user_id > 0 AND session_activity.user_id = post.user_id AND session_activity.unique_key = CAST(post.user_id AS BINARY))
WHERE (
(post.thread_id = ? AND (post.position >= 0 AND post.position < 10) )
)
AND (post.message_state IN ('visible'))
ORDER BY post.position ASC, post.post_date ASC
Params: 370235
Run Time: 0.004679
Select Type | Table | Type | Possible Keys | Key | Key Len | Ref | Rows | Extra |
---|
SIMPLE | thread | const | PRIMARY | PRIMARY | 4 | const | 1 | Using filesort |
SIMPLE | post | ref | thread_id_post_date,thread_id_position | thread_id_post_date | 4 | const | 1 | Using index condition; Using where |
SIMPLE | bb_code_parse_cache | eq_ref | content_type_id | content_type_id | 31 | const,xenforo.cc.post.post_id | 1 | Using where |
SIMPLE | user | eq_ref | PRIMARY | PRIMARY | 4 | xenforo.cc.post.user_id | 1 | |
SIMPLE | user_profile | eq_ref | PRIMARY | PRIMARY | 4 | xenforo.cc.post.user_id | 1 | |
SIMPLE | user_privacy | eq_ref | PRIMARY | PRIMARY | 4 | xenforo.cc.post.user_id | 1 | |
SIMPLE | signature_parse_cache | eq_ref | content_type_id | content_type_id | 31 | const,xenforo.cc.post.user_id | 1 | Using where |
SIMPLE | session_activity | eq_ref | PRIMARY | PRIMARY | 22 | xenforo.cc.post.user_id,func | 1 | Using where |
INSERT INTO xf_thread_view
(thread_id)
VALUES
(?)
Params: 370235
Run Time: 0.000086
UPDATE `xf_session` SET `expiry_date` = ? WHERE (session_id = '05196f286475a452e9dec295596596f0')
Params: 1716190278
Run Time: 0.001881
INSERT INTO xf_session_activity
(user_id, unique_key, ip, controller_name, controller_action, view_state, params, view_date, robot_key)
VALUES
(?, ?, ?, ?, ?, ?, ?, ?, ?)
ON DUPLICATE KEY UPDATE
ip = VALUES(ip),
controller_name = VALUES(controller_name),
controller_action = VALUES(controller_action),
view_state = VALUES(view_state),
params = VALUES(params),
view_date = VALUES(view_date),
robot_key = VALUES(robot_key)
Params: 0, , , XenForo_ControllerPublic_Thread, Index, valid, thread_id=370235, 1716186678,
Run Time: 0.000112
INSERT INTO xf_bb_code_parse_cache
(content_type, content_id, parse_tree, cache_version, cache_date)
VALUES (?, ?, ?, ?, ?)
ON DUPLICATE KEY UPDATE parse_tree = VALUES(parse_tree),
cache_version = VALUES(cache_version),
cache_date = VALUES(cache_date)
Params: post, 376871, a:16:{i:0;s:18:"据外媒报道,";i:1;a:4:{s:3:"tag";s:1:"b";s:6:"option";N;s:8:"original";a:2:{i:0;s:3:"[B]";i:1;s:4:"[/B]";}s:8:"children";a:1:{i:0;s:93:"发表在《自然》上的一项新研究概述了一种新型癌症疫苗的长期疗效。";}}i:2;s:265:"该研究跟踪了8名皮肤癌患者并发现这种实验性治疗可在4年后对癌细胞产生持久持久的免疫反应。在新研究中,正在研究的个性化癌症疫苗类型集中于新抗原,即仅针对在癌细胞表面发现的突变分子。
";i:3;a:4:{s:3:"tag";s:4:"left";s:6:"option";N;s:8:"original";a:2:{i:0;s:6:"[LEFT]";i:1;s:7:"[/LEFT]";}s:8:"children";a:1:{i:0;s:210:"为了研发出一种能针对每位患者的个性化疫苗,研究人员使用了血液和肿瘤样本来创造了一种高度特异性和定制化的治疗方法以帮助免疫系统瞄准并摧毁肿瘤。";}}i:4;s:2:"
";i:5;a:4:{s:3:"tag";s:4:"left";s:6:"option";N;s:8:"original";a:2:{i:0;s:6:"[LEFT]";i:1;s:7:"[/LEFT]";}s:8:"children";a:1:{i:0;s:180:"这些个体化新抗原癌症疫苗的首次试验的早期结果是阳性。最初的测试集中在经手术切除肿瘤后被确定为复发风险较高的黑色素瘤患者。";}}i:6;s:2:"
";i:7;a:4:{s:3:"tag";s:4:"left";s:6:"option";N;s:8:"original";a:2:{i:0;s:6:"[LEFT]";i:1;s:7:"[/LEFT]";}s:8:"children";a:1:{i:0;s:291:"来自达纳法伯癌症研究所的Catherine Wu是这项新抗原疫苗研究的联合负责人,她表示长期的数据显示了极富前景的反应,免疫细胞不仅在几年后记得它们的原发肿瘤目标并且似乎还能学习如何识别新的黑色素瘤生物标记物。";}}i:8;s:2:"
";i:9;a:4:{s:3:"tag";s:4:"left";s:6:"option";N;s:8:"original";a:2:{i:0;s:6:"[LEFT]";i:1;s:7:"[/LEFT]";}s:8:"children";a:1:{i:0;s:266:"“这些发现表明,个人新抗原疫苗可以刺激黑色素瘤患者产生持久的免疫反应,”Wu说道,“我们发现证据表明,最初的靶向免疫反应在过去几年里已经扩大从而为患者提供了持续的预防疾病的保护。”";}}i:10;s:2:"
";i:11;a:4:{s:3:"tag";s:4:"left";s:6:"option";N;s:8:"original";a:2:{i:0;s:6:"[LEFT]";i:1;s:7:"[/LEFT]";}s:8:"children";a:1:{i:0;s:544:"据了解,这个初步试验只涉及了一个非常小的实验对象,只有8名患者。这些患者都在首次切除肿瘤手术后18周左右接受了名为NeoVax的疫苗治疗。四年后,所有8名患者仍然活着,并且其中6名仍处于完全缓解状态。不过有两名患者出现了肺转移癌。这两名患者都接受了免疫检查点抑制剂治疗。和Wu共同领导了这项研究的Patrick Ott则称,有迹象表明,经过新抗原训练的免疫T细胞能更好地靶向这两位患者的转移肿瘤。";}}i:12;s:2:"
";i:13;a:4:{s:3:"tag";s:6:"center";s:6:"option";N;s:8:"original";a:2:{i:0;s:8:"[CENTER]";i:1;s:9:"[/CENTER]";}s:8:"children";a:1:{i:0;a:4:{s:3:"tag";s:3:"img";s:6:"option";N;s:8:"original";a:2:{i:0;s:5:"[IMG]";i:1;s:6:"[/IMG]";}s:8:"children";a:1:{i:0;s:90:"https://rdimg.com/proxy/https://static.cnbetacdn.com/article/2021/0122/cf939ebfa9072e4.jpg";}}}}i:14;s:2:"
";i:15;a:4:{s:3:"tag";s:4:"left";s:6:"option";N;s:8:"original";a:2:{i:0;s:6:"[LEFT]";i:1;s:7:"[/LEFT]";}s:8:"children";a:1:{i:0;s:306:"这种个体化新抗原癌症疫苗可能将能开始提供极富前景的临床试验结果,不过在进入市场之前它们需要面临的最大障碍可能是生产所需的时间和费用。几年前,据估计,为一位患者生产一种疫苗可能需要10周时间,成本约为6万美元。";}}}, 1621686945, 1716186678
Run Time: 0.024549